BioSpace News Archive

Vertex Pharmaceuticals Incorporated today announced that five scientific abstracts about the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference (NACFC) taking place virtually November 2-5, 2021.

Curebase, a company committed to democratizing access to clinical studies, and Checkable Medical, a startup that offers unique at-home tests for strep throat, today announced a joint clinical trial designed to confirm the efficacy and accuracy of Checkable’s at-home strep throat test kits.

Edesa Biotech, Inc. today announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.

Verogen Inc., a dedicated developer of human identification products for sequencing and analysis of forensic genomic samples, is building on its partnership with Cellmark Forensic Services.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), today reported that the global Phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population.

Calyxt, Inc. (Nasdaq: CLXT) will hold a conference call on Thursday, November 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the third quarter ended on September 30, 2021.

SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN), today announces that Bilessglu® (Chiglitazar Sodium tablets), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of Type 2 Diabetes (T2DM) .

Prelude Corporation announced today selection for an oral scientific session presentation at the American Society of Radiation Oncology (ASTRO) 63rd Annual Meeting.

Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics today announced the presentation of eight posters during the Fall Clinical Dermatology Conference, which takes place Oct. 21-24, 2021.

Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021